Preventive or therapeutic composition for neurodegenerative diseases comprising colchicine and metformin as active ingredients

WO2024096461A3PCT designated stage expired Publication Date: 2024-11-07YOUN JU HO +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/016948
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-01
Filing Date
2023-10-29
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for degenerative nervous system diseases associated with TDP-43 protein aggregates, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease, are limited in effectiveness, with existing therapies primarily providing symptom relief and no clear mechanism of action, leading to a significant burden on patients and healthcare systems.

Method used

A pharmaceutical composition containing colchicine and metformin as active ingredients, which works synergistically to inhibit abnormal aggregation of TDP-43 protein by enhancing autophagy and chaperone activity, thereby preventing or treating neurodegenerative diseases like ALS and other TDP-43 proteinopathies.

Benefits of technology

The combination of colchicine and metformin effectively reduces TDP-43 protein aggregation, improving treatment outcomes for neurodegenerative diseases, including ALS, by increasing chaperone and autophagy gene expression, and can be administered in low doses to achieve maximum therapeutic effect with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023016948_07112024_PF_FP_ABST
    Figure KR2023016948_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a therapeutic composition using a combined drug comprising, as active ingredients, colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof, for treating, preventing, suppressing, ameliorating or slowing down the onset or development of neurodegenerative diseases, in particular, diseases associated with the formation of aggregates of TAR DNA-binding protein 43 (TDP-43), such as amyotrophic lateral sclerosis, etc. or such conditions. The inventors of the present invention confirmed that the above-stated diseases can be treated or prevented by using a combined agent of colchicine and metformin mixed together, a drug that was not used in the prior art, as a therapeutic agent for the above-stated degenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for the prevention or treatment of degenerative neurological diseases containing colchicine and metformin as active ingredients

[0001] The present invention relates to a therapeutic composition for treating, preventing, suppressing, improving or slowing down a disease associated with aggregate formation of TAR DNA-binding protein 43 (TDP-43), or the onset or development of such a condition, using a combination comprising colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as active ingredients.

[0002] Diseases related to the TDP-43 protein, etc., as mentioned above, are mainly degenerative neurological diseases, and diseases corresponding to such degenerative diseases include frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE), and diseases, disorders, and abnormalities related to TDP-43, especially related to TDP-43 aggregates, or TDP-43 proteinopathy.

[0003] The inventors of the present invention have confirmed that the above-mentioned disease can be treated or prevented by using a combination drug containing colchicine and metformin, which are drugs that have not been used in the prior art as a treatment for the above-mentioned degenerative disease.

[0004]

[0005] Degenerative neurological diseases, such as Parkinson's disease, Alzheimer's disease, and stroke, are ultimately known to be caused by cell death, which leads to nerve cell damage and loss. For example, in Parkinson's disease, the selective loss of dopaminergic neurons in the substantia nigra of the midbrain leads to dysfunction in the basal ganglia, which are involved in motor function organization, resulting in motor dysfunction such as persistent tremors, rigidity, bradykinesia, and postural instability.

[0006] In the above-described neurodegenerative diseases, the inventors of the present invention confirmed that a combination drug combining colchicine and metformin is particularly effective for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, which is highly related to the TDP-43 protein.

[0007] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rare neurodegenerative disease that causes progressive degeneration of motor neurons in the central nervous system, characterized by the death of nerve cells in the motor neurons. The exact pathogenesis of ALS and research on treatments have not yet been clearly confirmed, and the only drugs currently approved by the U.S. FDA for the treatment of ALS are riluzole and edaravone. Both drugs are known to help extend life expectancy by several months in patients or delay disease progression in the early stages, but there is still no fundamental cure for ALS.

[0008] It has been reported that approximately 10% of patients with Lou Gehrig's disease have a genetic cause, and the remaining 90% of patients are thought to be caused by immune, oxidative toxicity, excitotoxicity, environmental factors, or protein aggregation.

[0009] Among these, aggregation of a protein called TDP-43 is observed in more than 90% of Lou Gehrig's disease patients, and many research results have reported that this phenomenon may be an important cause of Lou Gehrig's disease.

[0010] TDP-43 is mainly present in the cell nucleus, and it is known that TDP-43 protein-related diseases are induced when TDP-43 aggregates accumulate in the cytoplasm. Recently, abnormal aggregation of TDP-43 in the cytoplasm was also found in the brains of patients with limbic-specific senile TDP-43 encephalopathy (LATE) dementia and Alzheimer's dementia.

[0011] The development of an effective treatment for amyotrophic lateral sclerosis (ALS), which is the main treatment target of the present invention, is causing considerable difficulties for the pharmaceutical industry because, as mentioned above, the clear mechanism that causes ALS disease has not yet been identified.

[0012] Riluzole (Rilutek, Sanofi) and edaravone (Radicut, Mitsubishi Tanabe Pharma) are the only approved treatments for ALS to date. However, riluzole is a neuroprotective drug that blocks glutamatergic neurotransmission in the central nervous system and prevents apoptosis (programmed cell death) of motor neurons, while edaravone suppresses oxidative stress caused by free radicals. Both of these treatments have only been confirmed to have symptom-relieving effects.

[0013] Therefore, there is a need to develop improved therapies for the treatment of TDP-43 proteinopathies such as ALS, and developing such effective therapies will not only contribute to improving the quality of life and life expectancy of patients with ALS, but will also significantly help reduce the cost burden of such diseases.

[0014] Regarding the TDP-43 proteinopathy provided in the present invention, there has not yet been research on a treatment method using a combination drug containing colchicine and metformin as active ingredients.

[0015]

[0016] The present invention is intended to solve the situation in which there is a lack of therapeutic agents for treating amyotrophic lateral sclerosis (ALS) associated with TDP-43 proteinopathy, and clear research on the disease has not been sufficiently conducted, making it a significant burden to develop a new therapeutic agent.

[0017] Accordingly, in the present invention, the therapeutic effect on the disease was continuously studied using a combination drug of colchicine and metformin, which had not been studied as a treatment for amyotrophic lateral sclerosis in the prior art, and as a result, it was confirmed that the combination drug was sufficiently effective, thereby completing the present invention.

[0018] Age-related brain disorders characterized by pathological protein aggregation in the central nervous system (CNS) and peripheral organs are a leading cause of disability and death worldwide. The protein that best characterizes the aggregates in Alzheimer's disease and related disorders is amyloid beta. Other disease-associated, aggregation-prone proteins that cause neurodegeneration include, but are not limited to, alpha-synuclein (αSyn), huntingtin, fused in sarcoma (FUS), dipeptide repeat proteins (DPRs) generated by the unconventional translation of C9orf72 repeat expansions, superoxide dismutase 1 (SOD1), and TDP-43. Among these, diseases associated with TDP-43 aggregates are generally referred to as TDP-43 proteinopathies, including, but not limited to, ALS and FTD.

[0019] Transactive response (TAR) DNA-binding protein 43 kDa (TDP-43) is a 414-amino acid protein encoded by the TARDBP gene on chromosome 1p36.2 (ALS10). TARDBP consists of six exons (exon 1 is noncoding; exons 2–6 are protein-coding). TDP-43 belongs to the heterologous ribonucleoprotein (hnRNP) family of RNA-binding proteins. TDP-43 contains five functional domains. It consists of two RNA recognition motifs (RRM1 and RRM2) with two highly conserved hexameric ribonucleoprotein 2 (RNP2) and octameric ribonucleoprotein 1 (RNP1) domains, a nuclear export signal (NES) and a nuclear localization signal (NLS) that allow the transport of bound mRNA between the nucleus and cytoplasm, and a C-terminal glycine-rich domain that mediates protein-protein interactions.

[0020] TDP-43 is involved in multiple aspects of RNA processing, including transcription, splicing, transport, and stabilization. It is a highly conserved, ubiquitously expressed protein with tightly autoregulated expression levels that continuously shuttle between the nucleus and cytoplasm, but is primarily localized within the nucleus. In 2006, TDP-43 was identified as a protein that accumulates in most cases of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), characterized by tau-negative, ubiquitin-positive inclusion bodies (termed FTLD-TDP).

[0021] Thirty-eight negative-dominant mutations in TDP-43 have been identified in patients with sporadic and familial ALS, as well as in hereditary FTD, primarily located in the glycine-rich domain. TDP-43 is inherently prone to aggregation, as demonstrated by sedimentation analysis, and this propensity is further enhanced by some of the ALS-associated TARDBP mutations that link TDP-43 aggregation to clinical disease manifestations.

[0022] In a cell model of TDP-43 proteinopathy, a combination of colchicine and metformin increased autophagy and chaperone activity, thereby reducing abnormal aggregation of TDP-43 protein or accumulation in the cytoplasm due to mislocalization of TDP-43 protein; however, these results have not been reported to date.

[0023] Autophagy is known to play an important role in maintaining cellular homeostasis by decomposing unnecessary proteins or abnormal organelles within the cell and recycling them as new energy sources. It is also known that deficiency or dysfunction of autophagy is closely related to various human diseases, including brain diseases.

[0024] Meanwhile, chaperones, which are involved in preventing protein misfolding and thus suppressing damage and death of nerve cells, are well known as a defense mechanism against protein aggregation and have been considered important targets in the field of neurodegenerative disease treatment.

[0025] The inventors of the present invention have first discovered that a complex composition of colchicine and metformin can effectively inhibit abnormal aggregation of TDP-43 protein, a major pathogenic factor of neurodegenerative diseases, and have also confirmed that the composition of the present invention exhibits a mechanism for selectively inducing chaperones and autophagy associated with neurodegenerative diseases.

[0026] From these results, the purpose of the present invention is to provide a colchicine and metformin complex composition for treating or preventing amyotrophic lateral sclerosis, such as Lou Gehrig's disease, which is associated with the TDP-43 protein.

[0027] In addition, the present invention aims to provide a pharmaceutical composition for preventing or treating degenerative nervous system brain diseases such as frontotemporal dementia, amyotrophic lateral sclerosis, Alexander's disease, arginine affinity neuropathy, ALS-parkinsonism-dementia complex of Guam, limbic-predominant age-related TDP-43 encephalopathy, chronic traumatic encephalopathy, Perry's syndrome, Alzheimer's disease, Down's syndrome, British familial dementia, Huntington's disease, Machado-Joseph's disease, hippocampal sclerosis dementia, inclusion body myositis, oculopharyngeal muscular dystrophy with rimmed vacuoles, myofibrillar myopathy, traumatic brain injury, dementia with Lewy bodies, and Parkinson's disease, which are diseases associated with the aggregation of TDP-43 proteins.

[0028] The technical problems to be solved by the present invention are not limited to the problems mentioned above, and various problems related to the above problems can be clearly understood by those with ordinary skill in the technical field pertaining to the present invention from the description below.

[0029]

[0030] In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of degenerative nervous system brain diseases such as amyotrophic lateral sclerosis represented by Lou Gehrig's disease, Parkinson's disease, Alzheimer's dementia or Pick's disease, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, spinocerebellar degeneration, cerebellar atrophy, multiple sclerosis, senile dementia caused by loss of nerve cells, stroke, post-traumatic stress disorder, and amnesia, which are associated with TDP-43 protein, and which comprises colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as main active ingredients.

[0031] Furthermore, the present invention provides a pharmaceutical composition for enhancing the therapeutic effect of the above diseases, comprising colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as main active ingredients. The pharmaceutical composition for enhancing the therapeutic effect is synonymous with a therapeutic adjuvant for preventing and treating Lou Gehrig's disease, which is the target disease of the present invention.

[0032] The pharmaceutical composition of the present invention can be manufactured in the form of a pharmaceutical composition for treating or preventing a degenerative nervous system disease, which additionally contains an appropriate carrier, excipient, or diluent commonly used in the manufacture of pharmaceutical compositions, wherein the carrier may include a non-naturally occurring carrier. Specifically, the pharmaceutical composition can be formulated and used in the form of powders, pills, granules, tablets, capsules, oral solutions, emulsions, suspensions, emulsions, syrups, aerosols, external preparations, sterile aqueous solutions, non-aqueous solutions, lyophilized preparations, suppositories, and sterile injections, respectively, according to a conventional method.

[0033] The pharmaceutical composition provided in the present invention may further include, in addition to a pharmacologically acceptable appropriate carrier, one or more ingredients selected from the group consisting of melatonin, creatine, magnesium, coenzyme Q10, vitamin D, vitamin B, vitamin E, L-serine, L-carnitine, and N-acetylcystein, which are effective for degenerative neurological diseases.

[0034] The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention, and the effective dosage level may be determined according to factors including the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the administration time, administration route and excretion rate of the composition of the present invention used, the treatment period, drugs used in combination or simultaneously with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it may be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that can achieve the maximum effect with the minimum amount without side effects.

[0035] The dosage of the pharmaceutical composition provided in the present invention can be determined by a person skilled in the art by considering the purpose of use, degree of toxicity of the disease, age, weight, sex, medical history of the patient, or type of substance used as an active ingredient, but it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects by considering all of the above factors.

[0036]

[0037] The pharmaceutical composition comprising colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as active ingredients provided in the present invention inhibits abnormal aggregation and mislocalization of TDP-43 protein due to the synergistic effect of the two ingredients, and due to this action, can effectively prevent or treat degenerative neurological diseases such as Lou Gehrig's disease.

[0038] The combination preparation provided by the present invention can effectively enhance the preventive or therapeutic effect of the above-mentioned disease by administering a low dose without using expensive conventional drugs, and thus will play a significant role in promoting human health and developing related industries such as healthcare.

[0039]

[0040] Figure 1 shows the quantification of the mRNA expression (AC) or protein expression (D) of the chaperone protein HSPB8 when human SH-SY5Y cells were treated with metformin, colchicine alone, or metformin / colchicine combined.

[0041] Figure 2 shows the quantification of TDP-43 aggregation using a TDP-43 aggregation kit when H2O2-treated human SH-SY5Y cells were treated with metformin, colchicine alone, or a combination of metformin and colchicine.

[0042] Figure 3 presents the results of immunofluorescence staining and fluorescence microscopy to observe the degree of TDP-43 aggregation when H2O2-treated human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine (A), and the quantification of the measured stress granules (B). In addition, the degree of TDP-43 aggregation was confirmed and quantified using filter retardation analysis (C).

[0043] Figure 4 shows the intracellular localization of TDP-25 observed by fluorescence microscopy (A) when SH-SY5Y cells transfected with human GFP-TDP-25 were treated with metformin and colchicine alone or with a combination of metformin and colchicine, and the degree of TDP-43 aggregation was quantified (C) by observing the expression of insoluble TDP-43 and soluble TDP-43 proteins (B). In Figure 4, blue fluorescence represents the nucleus with DAPI, and green fluorescence represents TDP-25 with GFP.

[0044] Figure 5 shows the quantification of the expression of TFEB mRNA, an autophagy transcription factor, when human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine.

[0045] Figure 6 shows the quantification of autophagy receptor SQSTM1 / p62 mRNA expression when human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine.

[0046] Figure 7 shows the quantification of the expression of autophagy marker MAP1LC3A mRNA when human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine.

[0047] Figure 8 shows the quantification of p62 protein expression when human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine.

[0048] Figure 9 shows the quantification of LC3-II protein expression when human SH-SY5Y cells were treated with metformin and colchicine alone or with a combination of metformin and colchicine.

[0049]

[0050] When a complex agent formed by including colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof as active ingredients provided in the present invention is administered to human SH-SY5Y cells, it was confirmed that the degree of aggregation of TDP-43 is reduced, and the present invention was completed based on this.

[0051]

[0052] The present invention is described in detail below.

[0053] Colchicine, the main active ingredient used in the present invention, is a substance extracted from plants of the genus Colchicum. It is a drug mainly used as an alternative drug for gout when non-steroidal anti-inflammatory drugs do not show a smooth therapeutic effect on gout, and is also used to treat familial Mediterranean fever, pericarditis, Behcet's disease, etc.

[0054] Metformin, another active ingredient used in the present invention, is a biguanide drug primarily used as a diabetes treatment due to its blood sugar-lowering effect. While the exact mechanism of action of metformin is unknown, it is known to inhibit cellular respiration in mitochondria and activate AMPK, thereby preventing glucagon-induced increases in cAMP concentration. Consequently, it inhibits PKA activity and thus suppresses glucose production.

[0055] Diseases associated with the expression of the TDP-43 protein described in the present invention include frontotemporal dementia (FTD, e.g., with or without sporadic or familial motor-neuron disease (MND), with progranulin (GRN) mutations, with C9orf72 mutations, with TARDBP mutations, with mutations in valosin-containing protein (VCP), linked to chromosome 9p, corticobasal degeneration, frontotemporal lobar degeneration (FTLD) with ubiquitin-positive TDP-43 inclusion bodies (FTLDTDP), neutrophilic granulomatosis, Pick's disease, semantic variant primary progressive aphasia (svPPA), behavioral variant FTD (bvFTD), nonfluent variant primary progressive aphasia (nfvPPA), etc.), amyotrophic lateral sclerosis (ALS, e.g., sporadic ALS, with TARDBP mutations, with angiogenin (ANG) mutations, etc. (AxD), Alexander disease (AxD), limbic-predominant age-related TDP-43 encephalopathy (LATE), chronic traumatic encephalopathy, Perry syndrome, Alzheimer's disease (AD, including sporadic and familial forms of AD), Down syndrome, British familial dementia, polyglutamine disorders (Huntington's disease and spinocerebellar ataxia type 3 (SCA3; also known as Machado-Joseph disease)), hippocampal sclerotic dementia and myopathies (sporadic inclusion body myositis, inclusion body myositis with mutations in the valosin-containing protein (VCP); also Paget's disease of bone and frontotemporal dementia), oculopharyngeal muscular dystrophy with rim vacuoles, myofibrillar myopathy with mutations in the myotilin (MYOT) gene or in the gene encoding desmin (DES), traumatic brain injury (TBI), dementia with Lewy bodies (DLB), or Parkinson's disease (PD).

[0056] The inventors of the present invention have confirmed through various experiments that abnormal aggregation of TDP-43 protein is reduced when colchicine and metformin are used in combination.

[0057] In one embodiment of the present invention, when the amount of TDP-43 protein aggregation inhibition was compared when colchicine alone, metformin alone, or colchicine and metformin were administered in combination to SH-SY5Y cells, a human neuroblastoma cell line, the aggregation reduction of the protein was greatest when colchicine and metformin were administered in combination.

[0058] In addition, in one embodiment of the present invention, when colchicine and metformin were administered in combination to the above cell line, it was shown that the abnormal aggregation of TDP-43 induced by oxidative stress was suppressed much more than when the drugs were administered alone.

[0059] In addition, in one embodiment of the present invention, when colchicine and metformin were administered together in a TDP-43 aggregation-cell model, the aggregation of TDP-43 was significantly inhibited compared to when the drugs were administered alone. The above results showed that when colchicine and metformin were administered together, abnormal aggregation of TDP-43 was inhibited by increasing the expression of cellular autophagy marker genes and chaperone proteins.

[0060] From the above results, it was confirmed that the pharmaceutical composition provided by the present invention increases the expression of chaperone genes in diseases mediated by accumulation in the cytoplasm due to abnormal aggregation of TDP-43 protein or mislocalization of TDP-43 protein, and also increases the expression of autophagy genes, and suppresses abnormal aggregation and mislocalization of TDP-43 protein, and through this, the present inventors completed the present invention.

[0061]

[0062] The term 'composite preparation' used in the present invention refers to a pharmaceutical composition provided in the present invention.

[0063] The composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in the manufacture of pharmaceutical compositions. In addition, the composition may be formulated and used in the form of powders, pills, granules, tablets, capsules, oral solutions, emulsions, suspensions, emulsions, syrups, aerosols, external preparations, sterile aqueous solutions, non-aqueous solutions, lyophilized preparations, suppositories, and sterile injections according to conventional methods, and preferably may be formulated and used in the form of unit dosage forms suitable for oral administration.

[0064]

[0065] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dosage level may be determined based on the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route of administration and the excretion rate, the duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to administer an amount that can achieve the maximum effect with the minimum amount without causing side effects by taking all of the above factors into consideration, and this can be easily determined by those skilled in the art.

[0066] The pharmaceutical composition of the present invention can be administered to a subject via various routes. All modes of administration are contemplated, including oral, rectal, intravenous, intramuscular, intraperitoneal, subcutaneous, intranasal, transdermal, intrauterine, epidural, or intracerebrovascular injection. The dosage of the pharmaceutical composition of the present invention is determined by the type of drug as the active ingredient, along with various other relevant factors, such as the disease to be treated, the route of administration, the patient's age, sex, and weight, and the severity of the disease.

[0067] Hereinafter, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples.

[0068]

[0069] Example 1

[0070] Whether the combined treatment of metformin and colchicine has a synergistic effect in increasing the expression of the chaperone protein HSPB8

[0071] SH-SY5Y cells, a human neuroblastoma cell line, were treated with metformin (0, 0.1, 0.5, 1, 2, 5 mM) or colchicine (0, 1, 10, 100, 500, 1000 nM) at various concentrations, and after 24 hours, the mRNA expression of the chaperone protein HSPB8 (Heat Shock Protein Family B (Small) Member 8) was observed, and the results are presented in Figure 1.

[0072] Compared to the approximately two-fold increase in HSPB8 mRNA expression by metformin or colchicine treatment alone, the combined treatment with metformin (5 mM) and colchicine (10, 100, 500, 1000 nM) resulted in a more than 20-fold increase in HSPB8 mRNA expression in a colchicine concentration-dependent manner (Figures 1A-1C).

[0073] Since it was confirmed that the combined treatment with metformin and colchicine had an additive effect on the mRNA expression of HSPB8, the HSPB8 protein expression was observed by fixing the concentration of metformin (5 mM) and colchicine (1000 nM). At this time, the protein expression of HSPB8 showed a minimal change by the treatment with metformin or colchicine alone, but it was confirmed that the combined treatment with metformin and colchicine had an additive effect of about 8-fold increase (Fig. 1D, in each figure) **P<0.01, * P<0.05 compared with normal cell group; ## P<0.01 compared to the colchicine alone group).

[0074]

[0075] Example 2

[0076] Whether the combination of metformin and colchicine inhibits the abnormal aggregation of TDP-43 induced by oxidative stress

[0077] SH-SY5Y cells, a human neuroblastoma cell line, were treated with metformin (0, 0.1, 0.5, 1, 2, 5 mM) or colchicine (0, 1, 10, 100, 500, 1000 nM) at different concentrations, and 24 hours later, 1 mM hydrogen peroxide (H2O2) was treated for 1 hour to induce oxidative stress.

[0078] Afterwards, the degree of TDP-43 aggregation in each sample was measured, and it was observed that 1 mM hydrogen peroxide (H2O2) significantly induced abnormal aggregation of TDP-43, and that treatment with metformin alone had no significant effect on TDP-43 aggregation induced by hydrogen peroxide (Fig. 2A), and treatment with colchicine alone also had a minimal effect (Fig. 2B).

[0079] However, when treated with a combination of metformin and colchicine, it was confirmed that TDP-43 aggregation induced by hydrogen peroxide was significantly inhibited compared to when treated with the drugs alone, and in particular, in the group treated with the highest concentration of colchicine (1000 nM) and metformin together, it was observed that the inhibition was almost to the level of normal cells (Fig. 2C).

[0080] The above results presented in Fig. 2 were confirmed once again using microscopy and cell proteins (Fig. 3). Hydrogen peroxide (H2O2) significantly induced TDP-43 aggregation in the cytoplasm, and treatment with metformin or colchicine alone did not inhibit TDP-43 aggregation in the cytoplasm, but combined treatment with metformin and colchicine inhibited TDP-43 aggregation to the level of normal cells (Figs. 3A, 3B). This result was confirmed once again in the Filter Retardation assay experiment of Fig. 3C (in the above figure). ** P<0.01 compared with normal cell group; ## P<0.01, # P<0.05 compared with the hydrogen peroxide group; $$ P<0.01, $ P<0.05 compared to the hydrogen peroxide + colchicine group alone).

[0081]

[0082] Example 3

[0083] Whether combined treatment with metformin and colchicine inhibits TDP-43 aggregation in a TDP-43 aggregation-cell model

[0084] To establish a model of TDP-43 protein aggregation in SH-SY5Y cells, a human neuroblastoma cell line, the GFP-TDP-25 plasmid was transfected into the cells, and it was confirmed that the transfected GFP-TDP-25 (GFP: green fluorescent protein) exists in the cytoplasm.

[0085] When the above cells were treated with metformin or colchicine alone, it was confirmed that TDP-25 abnormally present in the cytoplasm was not affected, but combined treatment with metformin and colchicine inhibited the accumulation of TDP-25 in the cytoplasm (Fig. 4A).

[0086] In addition, in the TDP-43 aggregation model using the GFP-TDP-25 plasmid, it was confirmed that single treatment with metformin (5 mM) or colchicine (1000 nM) slightly reduced the expression of insoluble TDP-43, but combined treatment with metformin and colchicine significantly reduced the expression of insoluble TDP-43 (Fig. 4B, 4C, in the above figures). ** P<0.01, * P<0.05 compared with normal cell group; ## P<0.01 compared to the colchicine alone group).

[0087]

[0088] Example 4

[0089] Whether the combined treatment of metformin and colchicine has a synergistic effect in increasing cellular autophagy.

[0090] SH-SY5Y cells, a human neuroblastoma cell line, were treated with metformin (0, 0.1, 0.5, 1, 2, 5 mM) or colchicine (0, 1, 10, 100, 500, 1000 nM) at various concentrations, and 24 hours later, the mRNA expression of TFEB (Fig. 5), an autophagy master transcription factor, SQSTM1 / p62 (Fig. 6), an autophagy receptor, and MAP1LC3A (Fig. 7), an autophagy marker, was observed.

[0091] Regarding the changes in mRNA expression of the TFEB, SQSTM1 / p62, and MAP1LC3A genes, metformin treatment alone showed no effect at all, while colchicine treatment alone showed an approximately 2- to 3-fold increase. In comparison, it was observed that the combined treatment of metformin (5 mM) and colchicine (10, 100, 500, 1000 nM) had an additive effect of more than 10-fold on the expression of the above genes (Figs. 5, 6, and 7).

[0092] In addition, to confirm the effect of metformin and colchicine on autophagy in the TDP-43 aggregation model, SH-SY5Y cells transfected with GFP-TDP-25 plasmid were treated with metformin (5 mM) and colchicine (1000 nM) alone or in combination. It was confirmed that the protein expression of p62 increased by the above treatment was significantly suppressed by the combination treatment of metformin and colchicine compared to the single treatment of metformin or colchicine (Fig. 8). In addition, it was confirmed that the expression of LC3-II was significantly increased by the combination treatment of metformin and colchicine compared to the single treatment of metformin or colchicine (Fig. 9, in the drawing). ** P<0.01, * P<0.05 compared with normal cell group; ## P<0.01, # P<0.05 compared to the colchicine alone group).

[0093]

[0094] As can be seen from the above results, abnormal aggregation of TDP-43 protein was hardly reduced by single treatment with metformin or colchicine, but co-administration of colchicine and metformin significantly inhibited the aggregation of the protein, which means that the two drugs exhibit a clear synergistic effect and can effectively prevent or treat amyotrophic lateral sclerosis, such as Lou Gehrig's disease.

[0095] The foregoing description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

[0096]

[0097] The present invention is industrially applicable.

Claims

1. A pharmaceutical composition for preventing or treating a degenerative nervous system disease, characterized in that the pharmaceutical composition comprises colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition for preventing or treating a degenerative neurological disease, characterized in that the degenerative neurological disease in paragraph 1 is a disease mediated by accumulation in the cytoplasm due to abnormal aggregation of TDP-43 protein or mislocalization of TDP-43 protein.

3. In the second paragraph, a pharmaceutical composition for preventing or treating a degenerative neurological disease characterized in that the disease mediated by abnormal aggregation of the TDP-43 protein or accumulation in the cytoplasm due to mislocalization of the TDP-43 protein is any one selected from the group consisting of frontotemporal dementia, amyotrophic lateral sclerosis, Alexander's disease, arginine adenopathy, ALS-parkinsonism-dementia complex of Guam, limbic-predominant age-related TDP-43 encephalopathy, chronic traumatic encephalopathy, Perry's syndrome, Alzheimer's disease, Down's syndrome, British familial dementia, Huntington's disease, Machado-Joseph's disease, hippocampal sclerosis dementia, inclusion body myositis, oculopharyngeal muscular dystrophy with rim vacuoles, myofibrillar myopathy, traumatic brain injury, dementia with Lewy bodies, and Parkinson's disease.

4. In the first paragraph, the pharmaceutical composition is characterized by increasing chaperone gene expression, increasing autophagy gene expression, and inhibiting abnormal aggregation and mislocalization of TDP-43 protein in a disease mediated by accumulation in the cytoplasm due to abnormal aggregation or mislocalization of TDP-43 protein, a pharmaceutical composition for preventing or treating a degenerative neurological disease.

5. A pharmaceutical composition for the prevention or treatment of a degenerative nervous system disease, characterized in that the pharmaceutical composition in paragraph 1 is formulated in the form of any one of preparations selected from oral, rectal, intravenous, intramuscular, intraperitoneal, subcutaneous, intranasal, intrauterine, intracerebrovascular, and transdermal administration.

6. A pharmaceutical composition for preventing or treating a degenerative nervous system disease, characterized in that the pharmaceutical composition in claim 1 is manufactured in any one dosage form selected from the group consisting of powder, pill, granule, tablet, capsule, liquid, emulsion, suspension, emulsion, syrup, aerosol, external preparation, sterile aqueous solution, non-aqueous solution, lyophilized preparation, suppository, and sterile injection.

7. A pharmaceutical composition for preventing or treating a degenerative nervous system disease, characterized in that the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of melatonin, creatine, magnesium, coenzyme Q10, vitamin D, vitamin B, vitamin E, L-serine, L-carnitine, and N-acetylcystein in the first paragraph.

Citation Information

Patent Citations

  • Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis

    KR1020070089926A

  • Manufacturing method of package device

    KR1020220132452A

  • Weight generating device for muscular exercise

    KR102401395B1

  • New combination therapies for treating neurological disorders

    WO2013061161A2